MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2016.04.035

Медицинская библиотека · JACC. Cardiovascular interventions · 2016

Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.

Felix Cordula M, Fam Jiang Ming, Diletti Roberto, Ishibashi Yuki, Karanasos Antonios, Everaert Bert R C, van Mieghem Nicolas M D A, Daemen Joost, de Jaegere Peter P T, Zijlstra Felix, Regar Evelyn S, Onuma Yoshinobu, van Geuns Robert-Jan M

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study sought to report on clinical outcomes beyond 1 year of the BVS Expand registry.

BACKGROUND

Multiple studies have proven feasibility and safety of the Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California). However, data on medium- to long-term outcomes are limited and available only for simpler lesions.

METHODS

This is an investigator-initiated, prospective, single-center, single-arm study evaluating performance of the BVS in a lesion subset representative of daily clinical practice, including calcified lesions, total occlusions, long lesions, and small vessels. Inclusion criteria were patients presenting with non-ST-segment elevation myocardial infarction, stable/unstable angina, or silent ischemia caused by a de novo stenotic lesion in a native previously untreated coronary artery. Procedural and medium- to long-term clinical outcomes were assessed. Primary endpoint was major adverse cardiac events, defined as a composite of cardiac death, myocardial infarction, and target lesion revascularization.

RESULTS

From September 2012 to January 2015, 249 patients with 335 lesions were enrolled. Mean number of scaffolds per patient was 1.79 ± 1.15. Invasive imaging was used in 39%. In 38.1% there were American College of Cardiology/American Heart Association classification type B2/C lesions. Mean lesion length was 22.16 ± 13.79 mm. Post-procedural acute lumen gain was 1.39 ± 0.59 mm. Median follow-up period was 622 (interquartile range: 376 to 734) days. Using Kaplan-Meier methods, the MACE rate at 18 months was 6.8%. Rates of cardiac mortality, myocardial infarction, and target lesion revascularization at 18 months were 1.8%, 5.2%, and 4.0%, respectively. Definite scaffold thrombosis rate was 1.9%.

CONCLUSIONS

In our study, BVS implantation in a complex patient and lesion subset was associated with an acceptable rate of adverse events in the longer term, whereas no cases of early thrombosis were observed.

Для цитирования: Felix Cordula M, Fam Jiang Ming, Diletti Roberto, Ishibashi Yuki, Karanasos Antonios, Everaert Bert R C, van Mieghem Nicolas M D A, Daemen Joost, de Jaegere Peter P T, Zijlstra Felix, Regar Evelyn S, Onuma Yoshinobu, van Geuns Robert-Jan M. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.. JACC. Cardiovascular interventions. 2016. DOI: 10.1016/j.jcin.2016.04.035.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.